Intuitive Surgical (ISRG) tumbled nearly 8% to $541.00 on Thursday after the company released a preliminary financial report that featured a disappointing outlook for 2026.
The drop occurred despite the robotic surgery pioneer beating revenue expectations for both the fourth quarter and the full year of 2025.
| Current Price | $541.00 |
| Daily Change | -7.70% 🔴 |
| Day Range | $535.69 – $553.74 |
| 52-Week Range | $425.00 – $616.00 |
The primary catalyst for the selloff was management’s 2026 guidance for da Vinci procedure growth, which signaled a significant deceleration compared to recent expansion rates.
Investors pivoted away from the stock as the forecasted growth failed to meet Wall Street’s higher expectations for the coming year.
According to Investor's Business Daily, the stock's decline represents a “growth disappointment” that overshadowed a double-digit revenue beat.
This reaction highlights investor sensitivity to procedural adoption rates and hospital capital spending constraints.
Key Takeaways
- ISRG stock fell nearly 8% after forecasting 2026 procedure growth of 13% to 15%.
- Preliminary Q4 2025 revenue reached $2.87 billion, surpassing analyst estimates of $2.73 billion.
- The company placed 532 da Vinci systems in Q4, including 303 of the new da Vinci 5 models.
- Analysts at Evercore ISI noted that 90% of the Q4 sales beat was driven by system revenue rather than recurring procedures.
- Intuitive Surgical significantly underperformed its medical device peers, which rose about 1.5% on average today.
| 🟢 Bull Case | 🔴 Bear Case |
|---|---|
| • Q4 Revenue Beat: ~$2.87B vs $2.73B est. | • 2026 Guidance Miss: 13-15% vs 17% est. |
| • dV5 Placements: 303 systems in Q4 | • Ion Placement Decline: 42 vs 69 YoY |
| • FY25 Revenue Growth: Up 21% YoY | • Insider Selling: ~$63.5M in last 90 days |
Why Did Intuitive Surgical (ISRG) Stock Drop Today?
Intuitive Surgical shares fell about 7.7% as the market reacted to a “lackluster” outlook for its core business.
While the company reported record-breaking revenue for the 2025 fiscal year, the updated 2026 guidance suggested that the pace of surgical robotic adoption may be cooling.
Market data indicates that the decline was a stock-specific reaction to the company’s internal projections.
While ISRG fell sharply, the broader medical devices sector remained largely positive, indicating that the selling pressure was not tied to a wider industry downturn but rather concerns surrounding this particular large cap stock.
What Triggered ISRG's Decline? The 2026 Guidance Miss
The specific trigger for the plunge was the 2026 forecast for da Vinci procedure growth, which the company set between 13% and 15%.
This range is a notable step down from the 18% growth achieved in 2025 and falls short of the 17% expansion that analysts had projected for this prominent growth stock.
As reported by GlobeNewswire, this more measured pace of expansion may be the result of tightening hospital capital budgets.
Additionally, market analysis suggests that the international rollout of the da Vinci 5 system faces pricing and reimbursement headwinds that could slow near-term adoption.
Beyond the Guidance: ISRG's Strong Q4 & FY25 Performance
Despite the negative forward-looking sentiment, Intuitive Surgical’s actual 2025 performance was robust.
Preliminary Q4 revenue rose 19% year-over-year to approximately $2.87 billion. Full-year 2025 revenue reached roughly $10.06 billion, representing a 21% increase compared to the previous year.
System placements also remained strong, with 532 da Vinci systems placed in the final quarter of 2025, up from 493 in the prior year.
CEO Dave Rosa noted that the company saw “increased adoption and utilization” across its surgical platforms, with total da Vinci procedures exceeding 3.1 million for the full year.
What Are Analysts Saying About Intuitive Surgical (ISRG)?
Wall Street remains divided on the stock's near-term potential following the updated guidance, though investors using the best stock analysis apps can track these shifting price targets in real-time.
BTIG recently raised its price target for Intuitive Surgical to $616, citing the long-term positive impact of the da Vinci 5 system.
However, other analysts have expressed caution regarding the quality of the recent revenue beat.
Vijay Kumar of Evercore ISI, who maintains an “in-line” rating with a $580 price target, highlighted that 90% of the Q4 sales beat was linked to system revenue.
This can be more volatile than the recurring revenue generated by surgical procedures and instruments.
How Does ISRG's Performance Compare to Medical Device Peers?
Intuitive Surgical’s decline stood in stark contrast to the rest of the medical device industry.
While ISRG fell nearly 8%, the industry average change for the day was a gain of roughly 1.5%.
Peers like Alphatec Holdings (ATEC) surged almost 10%, while Medtronic (MDT) and Globus Medical (GMED) also posted gains.
| Company | Symbol | Daily Change | Performance |
|---|---|---|---|
| Alphatec Holdings | ATEC | +9.59% | Outperform |
| Globus Medical | GMED | +1.55% | Outperform |
| Medtronic plc | MDT | +0.25% | Underperform |
| Industry Avg | – | +1.45% | – |
| Intuitive Surgical | ISRG | -7.70% | Underperform |
Other specialized peers like TransMedics Group (TMDX) rose over 1%.
This divergence suggests that investors are currently more concerned about Intuitive's specific growth trajectory than the health of the broader healthcare equipment market.
Are Insiders Selling ISRG Stock, and What Does it Mean?
Recent insider activity has added a layer of caution for some investors, leading many to evaluate when to sell a stock following negative guidance.
Over the past 90 days, company insiders have sold approximately 114,007 shares, valued at roughly $63.5 million.
According to market analysis, Senior Vice President Mark Brosius sold 4,500 shares on December 12.
While executive sales are often planned in advance for personal financial reasons, the volume of selling leading up to the tempered 2026 outlook has caught the attention of retail investors.
What Should Intuitive Surgical (ISRG) Investors Watch Next?
Investors should closely monitor the continued adoption of the da Vinci 5 system, which accounted for 303 of the company's total placements in Q4.
The success of this newer platform is critical to maintaining market leadership as older systems are replaced.
Additionally, the performance of the Ion system bears watching.
While worldwide procedures grew, Ion system placements declined to 42 in Q4, down from 69 in the prior year.
Any further softening in Ion demand or continued hospital capital spending constraints could provide additional headwinds for the stock in the coming quarters.
| Time Period | Price Change | Performance |
|---|---|---|
| 1 Month | -3.25% | 🔴 |
| 3 Months | +24.27% | 🟢 |
| 6 Months | +4.88% | 🟢 |
| 1 Year | +0.46% | 🟢 |
The Bottom Line
Intuitive Surgical’s sharp decline underscores the market’s high expectations for the robotic surgery leader.
While the company delivered record revenue in 2025, the forecasted slowdown for 2026 has forced a re-evaluation of the stock's near-term valuation.
Although the company maintains a dominant position with millions of procedures performed annually, it must now navigate a landscape of tightening hospital budgets and international reimbursement challenges.
The coming months will reveal if the da Vinci 5 rollout can overcome these hurdles and return the company to the higher growth rates investors have come to expect.
